CD8A and neoplasm: Cancer immunotherapy targeting T cells, such as immune checkpoint inhibitors (ICIs), restores the tumor-killing effect of CD8+ T cells by combating the negative immune regulators and has achieved breakthroughs in cancer treatment (4).